Tarsons Products has released the complete transcript of its Q3FY26 earnings conference call held on February 06, 2026, providing detailed insights into the company's financial performance and strategic outlook. The transcript, uploaded to the company's website and shared with stock exchanges under Regulation 30 of SEBI regulations, offers comprehensive management commentary on quarterly results and operational developments.

Conference Call Documentation and Compliance

The company formally notified BSE and NSE on February 11, 2026, about the availability of the earnings conference call transcript. The document was digitally signed by Santosh Kumar Agarwal, CFO, Company Secretary & Compliance Officer, ensuring regulatory compliance and transparency for stakeholders.

Q3FY26 Financial Performance Highlights

During the conference call, management discussed the company's mixed financial performance for Q3FY26. Consolidated revenue grew 12.8% year-on-year to ₹1,078.93 million, while net profit declined to ₹50.36 million from ₹52.59 million in Q3FY25. The company emphasized evaluating performance on cash PAT basis due to accelerated depreciation from new facility investments.

Strategic Capacity Expansion and New Product Lines

Management highlighted the partial commissioning of the Panchla facility, with bioprocess containers already in production and generating sales in domestic and international markets. The facility has potential revenue capacity exceeding ₹150.00 million at full utilization. Cell culture products are expected to commence production in Q4FY26, requiring initial sampling and customer validation processes.

Aryan Sehgal, Promoter & Whole Time Director, emphasized the company's positioning to capitalize on government initiatives supporting the biopharmaceutical sector, including the ₹100.00 billion allocation over five years for India's biologics ecosystem development.

Market Dynamics and Competitive Landscape

The management addressed competitive pressures in domestic markets, attributing pricing challenges to excess capacity created during the COVID period. Despite competitive headwinds, the company reported operating at near full capacity in existing plants and expects stronger revenue growth in FY27 as new capacities ramp up.

International Business and Trade Agreements

Management expressed optimism about international market prospects following potential India-EU and India-US trade agreements. The India-US FTA could provide significant benefits by reducing tariffs from 50% to 18%, while the India-EU FTA would eliminate the current 6% duty. The company's German subsidiary Nerbe showed 22% revenue growth in Q3FY26, primarily due to rupee depreciation against the Euro.

Working Capital and Inventory Management

CFO Santosh Agarwal detailed the company's working capital cycle of 125 days, with inventory comprising raw materials worth ₹41.00 million, finished goods worth ₹39.00 million, and other components. The management expects inventory optimization as revenue scales up with new product launches and capacity utilization improvements.

Tarsons Products Limited has announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company published these results in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The company demonstrated solid financial performance during the third quarter of FY26. The results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 06, 2026.

Quarterly Financial Results

Nine Months Performance

For the nine months ended December 31, 2025, Tarsons Products reported total income from operations of ₹2,573.87 crores compared to ₹2,387.67 crores in the corresponding period of the previous year. Net profit after tax for the nine-month period stood at ₹171.94 crores versus ₹270.02 crores in the previous year.

Consolidated Results

On a consolidated basis, the company reported total income from operations of ₹1,163.15 crores for Q3 FY26, compared to ₹965.26 crores in the same quarter of the previous year. Consolidated net profit after tax was ₹50.36 crores for the quarter, compared to ₹52.59 crores in Q3 FY25.

Key Financial Metrics

Regulatory Compliance

The financial results were published in newspapers on February 08, 2026, as required under Regulation 47 of the SEBI Listing Regulations. The publications appeared in:

• Financial Express (English - National Publication)
• Aajkal (Bengali - Kolkata Publication)

The complete financial results along with Limited Review Reports are available on the stock exchange websites at www.bseindia.com and www.nseindia.com , as well as on the company's website at www.tarsons.com .

Board Approval

The results were formally approved at the Board of Directors meeting held on Friday, February 06, 2026. The company has provided QR codes for easy access to the complete financial statements and related documents through digital platforms.